

COC STD 4.7: Quality Study – 2017

Rajasree Roy, MD –SFH Oncology

HER2 – Extended RAS Gene Mutation Testing in Metastatic Colorectal Cancer – ASCO Guidelines

- ▶ **ASCO guidelines:** October 5, 2015, 10.1200/JCO.2015.63.9674
 - ▶ Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- ▶ Multiple phase II and Phase III trials indicated that patients whose tumors harbor *KRAS* or *NRAS* mutations in exon 2 (codons 12, 13), exon 3 (codons 59, 61) and exon 4 (codons 117, 146) are unlikely to derive benefit from treatment with anti-EGFR monoclonal antibody therapy (currently cetuximab or panitumumab)

Methods:

- ▶ Retrospective chart review of all patients with stage IV colon cancer diagnosed from 1/1/2015 to 12/31/15 who are candidates for chemotherapy

Demographics

- ▶ 18 patients with stage IV CRC, M:F 10:8, age 50-96
- ▶ 8 patients had right sided primary, 6 patients had left sided primary, 4 unknown
- ▶ 5 patients alive and 13 patients died
- ▶ **6 patients had documented K-RAS testing, 4 positive and 2 negative.**

- ▶ **3 positive patients did not get anti-EGFR treatment, 1 patient treated elsewhere**
- ▶ 5 patients treated outside and information not available
- ▶ 5 patients referred to hospice after diagnosis
- ▶ 1 patient NE carcinoma
- ▶ 1 patient lost to follow

Recommendation: Maintain current standard.